Comprehensive genetic analysis to identify causative mutations of diseases in the field of pediatric surgery
Ontology highlight
ABSTRACT:
DISEASE(S): Congenital Digestive Tract Atresia, Gastrointestinal Motility Disorder, Intestinal Malrotation, Congenital Gastrointestinal Malformation, Hirschsprung Disease, Anorectal Malformation, Neonatal Gastrointestinal Perforation, Pancreaticobiliary Maljunction, Biliary Atresia, Portal Hypertension, Liver Fibrosis, Congenital Airway Disease, Pulmonary Cystic Disease, Diaphragmatic Hernia, Vascular Or Lymphatic Malformation, Tumor Disease, Abdominal Wall Dysplasia, Renal Urological Malformation, Malformation Syndrome, Etc
PROVIDER: 2653767 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:The outcome for children with high-grade gliomas (HGG) remains dismal, with a two-year survival rate of only 10-30%. Approximately half of pediatric HGGs are diffuse intrinsic pontine glioma (DIPG), a brainstem tumor that arises almost exclusively in children. Genome-wide analyses of copy number imbalances previously showed that platelet derived growth factor receptor alpha (PDGFRA) is the most frequent target of focal amplification in pediatric HGGs. To determine whether the PDGFRA is also targeted by more subtle mutations not detected by copy number analysis, we sequenced all PDGFRA coding exons from a cohort of pediatric HGGs. Somatic activating mutations were identified in 14.4% (13/90) of non-brainstem pediatric HGGs and 4.7% (2/43) of DIPGs, including missense mutations and in-frame deletions and insertions not previously described. 40% of tumors with mutation showed concurrent amplification, while 60% carried heterozygous mutations. Six different mutations impacting different domains all resulted in ligand-independent receptor activation that was blocked by small molecule inhibitors of PDGFR. Expression of mutants in p53-null primary mouse astrocytes conferred a proliferative advantage in vitro, and generated HGGs in vivo with complete penetrance when implanted into brain. The gene expression signatures reflected the spectrum of human diffuse HGGs. PDGFRA intragenic deletion of exons 8 and 9 were previously shown in adult HGG, but were not detected in 83 non-brainstem pediatric HGG and 57 DIPGs. Thus, a distinct spectrum of mutations confers constitutive receptor activation and oncogenic activity to PDGFR in childhood HGG. To better understand the consequence of PDGFRα mutation in pediatric gliomagenesis, retroviral constructs expressing wild-type PDGFRα or six selected PDGFRα mutants that affect different regions of the receptor were generated for functional studies. p53-null primary mouse astrocyte (PMA) cultures were chosen as a relevant cellular background to assess PDGFRα function.
2013-11-06 | E-GEOD-46190 | biostudies-arrayexpress
Project description:The outcome for children with high-grade gliomas (HGG) remains dismal, with a two-year survival rate of only 10-30%. Approximately half of pediatric HGGs are diffuse intrinsic pontine glioma (DIPG), a brainstem tumor that arises almost exclusively in children. Genome-wide analyses of copy number imbalances previously showed that platelet derived growth factor receptor alpha (PDGFRA) is the most frequent target of focal amplification in pediatric HGGs. To determine whether the PDGFRA is also targeted by more subtle mutations not detected by copy number analysis, we sequenced all PDGFRA coding exons from a cohort of pediatric HGGs. Somatic activating mutations were identified in 14.4% (13/90) of non-brainstem pediatric HGGs and 4.7% (2/43) of DIPGs, including missense mutations and in-frame deletions and insertions not previously described. 40% of tumors with mutation showed concurrent amplification, while 60% carried heterozygous mutations. Six different mutations impacting different domains all resulted in ligand-independent receptor activation that was blocked by small molecule inhibitors of PDGFR. Expression of mutants in p53-null primary mouse astrocytes conferred a proliferative advantage in vitro, and generated HGGs in vivo with complete penetrance when implanted into brain. The gene expression signatures reflected the spectrum of human diffuse HGGs. PDGFRA intragenic deletion of exons 8 and 9 were previously shown in adult HGG, but were not detected in 83 non-brainstem pediatric HGG and 57 DIPGs. Thus, a distinct spectrum of mutations confers constitutive receptor activation and oncogenic activity to PDGFR in childhood HGG.
2013-11-06 | GSE46190 | GEO
Project description:A comprehensive genomic study of pediatric malignancy
| PRJNA588314 | ENA
Project description:A comprehensive genomic study of pediatric malignancy
| PRJNA588315 | ENA
Project description:Background & Aims: Most inflammatory bowel diseases (IBDs) are classic polygenic disorders represented by common alleles. However, multiple determinants of very early-onset IBD characterized by a more extensive disease course remain largely unknown. The present study aimed to define the genetic architecture of pediatric and adult-onset IBDs in the Polish population. Results: Of 82 SNPs validated/replicated for association with IBD, a novel BRD2 (rs1049526) association was found in both pediatric (OR= 2.35) and adult (OR= 2.66) patients. Thirty SNPs were shared between pediatric and adult patients; 22 and 30 were unique to adult-onset and pediatric-onset IBD, respectively. WES identified numerous rare/infrequent, potentially deleterious variants in IBD-associated or innate immunity-associated genes. Both groups of variants were over-represented in affected children. Two highly deleterious homozygous variants, HLA-DRB1 c.565_566insC and NCF4 p.Arg8Trp, were found in two affected children, and WAS p.Glu131Lys was found in one child and one adult patient. Conclusions: Our GWAS revealed differences in the polygenic architecture of pediatric- and adult-onset IBD. A significant accumulation of rare/low frequency deleterious variants in affected children suggests a contribution by yet unexplained genetic components.
2017-01-01 | GSE79094 | GEO
Project description:<p><strong>BACKGROUND:</strong> Metabolites that are direct read-outs of the functional status of cells, tissues, and organs can be more closely associated with phenotype compared to other omics profiles. Previous studies showed the analytical validity of metabolomic platforms and demonstrated a utility in interpreting the impact of genetic variants.</p><p><strong>METHODS:</strong> To explore the utility of metabolomics in the context of precision medicine, we used an untargeted ultrahigh performance liquid chromatography-tandem mass spectroscopy to characterize plasma samples collected from generally healthy individuals and a deeply phenotyped cohort with various pediatric diseases.</p><p><strong>RESULTS:</strong> A total of 1244 metabolites including 224 xenobiotic compounds were quantitatively measured for 169 individuals and thus revealed complex correlation structure within and between metabolic pathways. As proofs-of-concept, perturbations of phenylalanine and tyrosine metabolic pathways in a patient with phenylketonuria and carbohydrate metabolism in patients with diabetes mellitus were recapitulated as well as highlighting other biomarkers such as 1,5−anhydroglucitol for monitoring glycemic control. We discovered multiple metabolites that were significantly associated with different diseases using an exposome-wide association analysis framework. Amino acids showed significantly changed in patients with congenital heart diseases, and multiple lipid compounds were significant for Crohn’s disease. Notably, gut microbial products showed different concentrations with the use of antibiotics. Each xenobiotic compound showed a distinct correlation pattern with endogenous metabolites.</p><p><strong>CONCLUSIONS:</strong> Untargeted metabolomics could be a powerful precision medicine platform in itself or in combination with WES. The impact of exogenous exposures such as microbial products, drugs and environmental toxicants can be directly estimated by monitoring internal exposome, enabling the discovery of novel diagnosis and treatment biomarkers in diverse diseases. A repository of metabolomics data is required, which will enable the comparison between different platforms and concentrations of thousands of metabolites across individuals.</p>
2024-05-14 | MTBLS948 | MetaboLights
Project description:Genome wide DNA methylation profiling of pediatric acute myeloid leukemia (AML) from diagnostic and relapsed specimens.
2021-12-15 | GSE190931 | GEO
Project description:A collection of oropharyngeal, skin, sputum and fecal swabs from pediatric cystic fibrosis patients.
2018-05-25 | MSV000082406 | GNPS
Project description:Long non-coding RNAs (lncRNAs) play an important role in gene regulation and contribute to tumorigenesis. While pan-cancer studies of lncRNA expression have been performed for adult malignancies, the lncRNA landscape across pediatric cancers remains largely uncharted. Here, we curated RNA sequencing data for 1,044 pediatric leukemia and extra-cranial solid tumors and integrated paired tumor whole genome sequencing and epigenetic data in relevant cell line models to explore lncRNA expression, regulation, and association with cancer. A total of 2,657 lncRNAs were robustly expressed across six pediatric cancers, including 1,142 exhibiting histotype-elevated expression. DNA copy number alterations contributed to lncRNA dysregulation at a proportion comparable to protein coding genes. Application of a multi-dimensional framework to identify and prioritize lncRNAs impacting gene networks revealed that lncRNAs dysregulated in pediatric cancer are associated with proliferation, metabolism, and DNA damage hallmarks. Analysis of upstream regulation via cell-type specific transcription factors further implicated distinct histotype-elevated and developmental lncRNAs. Integration of these analyses prioritized lncRNAs for experimental validation, and silencing of TBX2-AS1, the top-prioritized neuroblastoma-specific lncRNA, resulted in significant growth inhibition of neuroblastoma cells, confirming the computational predictions. Taken together, these data provide a comprehensive characterization of lncRNA regulation and function in pediatric cancers and pave the way for future mechanistic studies.
2023-07-31 | GSE238166 | GEO
Project description:Most adult patients have a D816V mutation in phosphotransferase domain (PTD), we have described that half of the children carry mutations in extracellular domain (ECD). KIT-ECD versus IT-PTD-mutants were introduced into rodent Ba/F3, EML, Rat2 and human TF1 cells to investigate their biological effect. ECD- and PTD-mutants also displayed distinct whole-genome transcriptional profiles in EML cells. We observed differences in their signaling properties: they both activated STAT pathways, whereas AKT pathway was only activated by ECD-mutants. Consistently, AKT inhibitor suppressed ECD-mutant-dependent proliferation, clonogenicity and erythroid differentiation. Expression of myristoylated AKT restored erythroid differentiation in EMLPTD cells, suggesting the differential role of AKT in those mutants. Overall, our study implied different pathogenesis of pediatric versus adult mastocytosis, which might explain their diverse phenotypes.
2010-04-10 | GSE21255 | GEO